How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance

Trends in Parasitology

Volumn 27, Issue 2, 2011, Pages 67-72

  Hastings, Ian ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ;

ANTIMALARIAL DRUG RESISTANCE; CLINICAL TRIAL; HUMAN; MALARIA; MORBIDITY; MORTALITY; MULTICENTER STUDY; MUTATION RATE; SHORT SURVEY;

ANIMALS; ANTIMALARIALS; ARTEMISININS; DRUG RESISTANCE; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; HUMANS; MALARIA;

EID: 79251598067     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2010.09.005     Document Type: Short Survey

References (60)

1. Hastings I.M., D'Alessandro U. Modelling a predictable disaster: the rise and spread of drug-resistant malaria. Parasitol. Today 2000, 16:340-347.
2. Hyde J.E. Drug-resistant malaria. Trends Parasitol. 2005, 21:494-498.
3. Wernsdorfer W.H. The development and spread of drug-resistant malaria. Parasitol. Today 1991, 7:297-303.
4. Institute of Medicine Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance 2004, The National Acadamies Press.
5. Carrara V.I., et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLOS One 2009, 4:e4551.
6. Noedl H., et al. Evidence of artemisinin-resistant Malaria in Western Cambodia. N. Engl. J. Med. 2008, 359:2619-2620.
7. Dondorp A.M., et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 2009, 361:455-467.
8. Burki T. Artemisinin resistance could endanger fight against malaria. Lancet Infect. Dis. 2009, 9:213.
9. Enserink M. Malaria's drug miracle in danger. Science 2010, 328:844-846.
10. Anderson T.J.C., Roper C. The origins and spread of antimalarial drug resistance: lessons for policy makers. Acta Trop. 2005, 94:269-280.
11. Hastings I.M. The origins of antimalarial drug resistance. Trends Parasitol. 2004, 20:512-518.
12. Laufer M.K., Plowe C.V. Cotrimoxazole prophylaxis and malaria in Africa: Have the important questions been answered?. Am. J. Trop. Med. Hyg. 2006, 75:373-374.
13. Looareesuwan S., et al. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am. J. Trop. Med. Hyg. 1996, 54:62-66.
14. Hastings I.M., Ward S.A. Coartem in Africa - the beginning of the end?. J. Infect. Dis. 2005, 192:1303-1304.
15. Sisowath C., et al. The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop. Med. Int. Health 2007, 12:736-742.
16. Nsanzabana C., et al. Quantifying the evolution and impact of antimalarial drug resistance: drug use, spread of resistance and drug failure over a 12 year period in Papua New Guinea. J. Infect. Dis. 2010, 201:435-443.
17. Hartl D.L., Clark A.G. Principles of Population Genetics 2007, Sinauer Associates.
18. Crow J.F., Kimura M. An Introduction to Population Genetics Theory 1970, Harper & Row.
19. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 2004, 363:9-17. International Artemisinin Study Group.
20. Fisher R.A. The wave of advance of advantageous genes. Ann. Eugen. 1937, 7:355-369.
21. Morjan C.L., Rieseberg L.H. How species evolve collectively: implications of gene flow and selection for the spread of advantageous alleles. Mol. Ecol. 2004, 13:1341-1356.
22. Babiker H., et al. Impaired fitness of drug-resistant malaria parasites: evidence and implication on drug deployment policies. Expert Rev. Anti Infect. Ther. 2009, 7:581-593.
23. Hastings I.M., Donnelly M.J. The impact of antimalarial drug resistance mutations on parasite fitness, and its implications for the evolution of resistance. Drug Resist. Update 2005, 8:43-50.
24. Walliker D., et al. Fitness of drug-resistant malaria parasites. Acta Trop. 2005, 94:251-259.
25. Kublin J.G., et al. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J. Infect. Dis. 2003, 187:1870-1875.
26. Mita T., et al. Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. Am. J. Trop. Med. Hyg. 2003, 68:413-415.
27. Nkhoma S., et al. In vitro antimalarial susceptibility profile and PRCRT/PFMDR-1 genotypes of Plasmodium falciparum field isolates from Malawi. Am. J. Trop. Med. Hyg. 2007, 76:1107-1112.
28. Koella J.C., Antia R. Epidemiological models for the spread of anti-malarial resistance. Malaria J. 2003, 2:3.
29. Chaijaroenkul W., et al. In vitro antimalarial drug susceptibility in Thai border areas from 1998-2003. Malaria J. 2005, 4:37.
30. Anderson T.J.C., et al. Are transporter genes other than the chloroquine resistance locus (pfcrt) and multidrug resistance gene (pfmdr) associated with antimalarial drug resistance?. Antimicrob. Agents Chemother. 2005, 49:2180-2188.
31. Mu J., et al. Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nat. Genet. 2010, 42:268-271.
32. O'Neill P.M., et al. The molecular mechanism of action of artemisinin - The debate continues. Molecules 2010, 15:1705-1721.
33. Watkins W.M., Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulphadoxine: selective pressure for resistance is a function of long half-life. Trans. R. Soc. Trop. Med. Hyg. 1993, 87:75-78.
34. Ehrlich P. Chemotherapeutische Trypanosomen Studien. Berl. Klin. Wochenschr. 1907, 9:233-236.
35. Ehrlich P. Chemotherapeutische Trypanosomen Studien. Berl. Klin. Wochenschr. 1907, 10:280-283.
36. Watkins W.M., et al. The search for effective and sustainable treatments for falciparum malaria in Africa: a model of the selection of resistance by antifolate drugs and their combinations. Am. J. Trop. Med. Hyg. 2005, 72:163-173.
37. Sibley C., et al. A network to monitor antimalarial drug resistance: a plan for moving forward. Trends Parasitol. 2008, 24:43-48.
38. Boni M.F., et al. Benefits of using multiple first-line therapies against malaria. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14216-14221.
39. Attaran A., et al. WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet 2004, 363:237-240.
40. Meshnick S.R., Alker A.P. Amodiaquine and combination chemotherapy for malaria. Am. J. Trop. Med. Hyg. 2005, 73:821-823.
41. Curtis C.F., Otoo L.N. A simple model of the build-up of resistance to mixtures of anti-malarial drugs. Trans. R. Soc. Trop. Med. Hyg. 1986, 80:889-892.
42. Dye C., Williams B.G. Multigenic drug resistance among inbred malaria parasites. Proc. R. Soc. Lond., Ser. B: Biol. Sci. 1997, 264:61-67.
43. Hastings I.M. A model for the origins and spread of drug resistant malaria. Parasitology 1997, 115:133-141.
44. Hastings I.M., Watkins W.M. Tolerance is the key to understanding antimalarial drug resistance. Trends Parasitol. 2006, 22:71-77.
45. Hastings I.M., et al. The evolution of drug resistant malaria; the role of drug elimination half-life. Phil. Trans. R. Soc. Lond. Ser. B 2002, 357:505-519.
46. Hastings I.M. Malaria control and the evolution of drug resistance: an intriguing link. Trends Parasitol. 2003, 19:70-73.
47. Talisuna A.O., et al. Intensity of transmission and spread of gene mutations linked to chloroquine and sulphadoxine-pyrimethamine resistance in falciparum malaria. Int. J. Parasitol. 2003, 33:1051-1058.
48. Harrington W.E., et al. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:9027-9032.
49. Wargo A.R., et al. Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19914-19919.
50. Hastings I.M. Complex dynamics and stability of antimalarial drug resistance. Parasitology 2006, 132:615-624.
51. Picot S., et al. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malaria J. 2009, 8:89.
52. Paget-McNicol S., Saul A. Mutation rates in the dihydrofolate reductase gene of Plasmodium falciparum. Parasitology 2001, 122:497-505.
53. Rich S.M., et al. Malaria's eve: evidence of a recent population bottleneck throughout the world populations of Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:4425-4430.
54. Tian D., et al. Single-nucleotide mutation rate increases close to insertions/deletions in eukaryotes. Nature 2008, 455:105-108.
55. Hodgkinson A., et al. Cryptic variation in the human mutation rate. PLoS Biol. 2009, 7:e1000027.
56. Anderson T.J.C., et al. Gene copy number and malaria biology. Trends Parasitol. 2009, 25:336-343.
57. Rathod P.K., et al. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:9389-9393.
58. Sisowath C., et al. In vivo selection of Plasmodium falciparum pfmdr 1 86N coding alleles by Artemether-Lumefantrine (Coartem). J. Infect. Dis. 2005, 191:1014-1017.
59. Roper C., et al. Intercontinental spread of pyrimethamine-resistant malaria. Science 2004, 305:1124.
60. Sibley C., et al. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next?. Trends Parasitol. 2001, 17:582-588.